Aging-related dysregulation of dopamine and angiotensin receptor interaction

Neurobiology of Aging

Volumn 35, Issue 7, 2014, Pages 1726-1738

  Villar Cheda, Begoña ^a,b   Dominguez Meijide, Antonio ^a,b   Valenzuela, Rita ^a,b   Granado, Noelia ^b,c   Moratalla, Rosario ^b,c   Labandeira Garcia, Jose L ^a,b  

^a CIMUS University of Santiago de Compostela ^*  (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO CAJAL   (Spain)

Author keywords

Aging; Neurodegeneration; Neuroinflammation; Oxidative stress; Parkinson; Renin angiotensin system; Striatum

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR;

ADULT; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOWN REGULATION; ENZYME ACTIVITY; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBSTANTIA NIGRA; YOUNG ADULT;

AGING; NEURODEGENERATION; NEUROINFLAMMATION; OXIDATIVE STRESS; PARKINSON; RENIN-ANGIOTENSIN SYSTEM; STRIATUM;

AGING; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINERGIC NEURONS; DOWN-REGULATION; GENE EXPRESSION; INFLAMMATION; MALE; MICE; OXIDATIVE STRESS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, DOPAMINE; RENIN-ANGIOTENSIN SYSTEM; RISK; SUBSTANTIA NIGRA;

EID: 84903369174     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.01.017     Document Type: Article

References (74)

1. Ares-Santos S., Granado N., Oliva I., O'Shea E., Martin E.D., Colado M.I., Moratalla R. Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol. Dis. 2012, 45:810-820.
2. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
3. Basso N., Paglia N., Stella I., de Cavanagh E.M., Ferder L., del Rosario Lores Arnaiz M., Inserra F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept. 2005, 128:247-252.
4. Benigni A., Cassis P., Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol. Med. 2010, 2:247-257.
5. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J.Clin. Invest. 2009, 119:524-530.
6. Benigni A., Orisio S., Noris M., Iatropoulos P., Castaldi D., Kamide K., Rakugi H., Arai Y., Todeschini M., Ogliari G., Imai E., Gondo Y., Hirose N., Mari D., Remuzzi Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. Age (Dordr) 2013, 35:993-1005. 10.1007/s11357-012-9408-8.
7. Choi D.Y., Zhang J., Bing G. Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats. Neurobiol. Aging 2010, 31:1649-1653.
8. Chugh G., Lokhandwala M.F., Asghar M. Altered functioning of both renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in old rats. Hypertension 2012, 59:1029-1036.
9. Chugh G., Pokkunuri I., Asghar M. Renal dopamine and angiotensin II receptor signaling in age-related hypertension. Am. J. Physiol. Ren. Physiol. 2013, 304:F1-F7.
10. Colebrooke R.E., Humby T., Lynch P.J., McGowan D.P., Xia J., Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur. J. Neurosci. 2006, 24:2622-2630.
11. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Bakay R.A., Sladek J.R., Kordower J.H. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 2007, 26:56-65.
12. Cruz-Muros I., Afonso-Oramas D., Abreu P., Pérez-Delgado M.M., Rodríguez M., González-Hernández T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol. Aging 2009, 30:973-986.
13. Csiszar A., Ungvari Z., Koller A., Edwards J.G., Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J. 2003, 17:1183-1185.
14. Cui L., Nithipatikom K., Campbell W.B. Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells. Anal. Biochem. 2007, 369:27-33.
15. Darbin O. The aging striatal dopamine function. Parkinsonism Relat. Disord. 2012, 18:426-432.
16. Darmopil S., Martín A.B., De Diego I.R., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol. Psychiatry 2009, 66:603-613.
17. de la Fuente-Fernández R., Schulzer M., Kuramoto L., Cragg J., Ramachandiran N., Au W.L., Mak E., McKenzie J., McCormick S., Sossi V., Ruth T.J., Lee C.S., Calne D.B., Stoessl A.J. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann. Neurol. 2011, 69:803-810.
18. Färber K., Pannasch U., Kettenmann H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell Neurosci. 2005, 29:128-138.
19. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
20. Fornaretto M.G., Caccia C., Caron M.G., Fariello R.G. Dopamine receptors status after unilateral nigral 6-OHDA lesion. Autoradiographic and in situ hybridization study in the rat brain. Mol. Chem. Neuropathol. 1993, 19:147-162.
21. Garrido A.M., Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol. Cell Endocrinol. 2009, 302:148-158.
22. Garrido-Gil P., Valenzuela R., Villar-Cheda B., Lanciego J.L., Labandeira-Garcia J.L. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra. Brain Struct. Funct. 2013, 218:373-388.
23. Gildea J.J. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr. Opin. Nephrol. Hypertens. 2009, 18:28-32.
24. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Jhaveri V.V., Poczobutt A.M., Weyhenmeyer J.A., Zawada W.M. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2007, 2:1.
25. Granado N., Ares-Santos S., Oliva I., O'Shea E., Martin E.D., Colado M.I., Moratalla R. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol. Dis. 2011, 42:391-403.
26. Griendling K.K., Sorescu D., Ushio-Fukai M. NADPH oxidase. Role in cardiovascular biology and disease. Circ. Res. 2000, 86:494-501.
27. Hemming M.L., Selkoe D.J., Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 2007, 26:273-281.
28. Hudson J.L., Van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., Gerhardt G.A. Correlation of apomorphine and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 1993, 626:167-174.
29. Hurley P.J., Elsworth J.D., Whittaker M.C., Roth R.H., Redmond D.E. Aged monkeys as a partial model for Parkinson's disease. Pharmacol. Biochem. Behav. 2011, 99:324-332.
30. Hussain T., Abdul-Wahab R., Kotak D.K., Lokhandwala M.F. Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules. Hypertension 1998, 32:1054-1059.
31. Joglar B., Rodriguez-Pallares J., Rodríguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J.Neurochem. 2009, 109:656-669.
32. Khan F., Spicarová Z., Zelenin S., Holtbäck U., Scott L., Aperia A. Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am. J. Physiol. Ren. Physiol. 2008, 295:F1110-F1116.
33. Kramer P.F., Christensen C.H., Hazelwood L.A., Dobi A., Bock R., Sibley D.R., Mateo Y., Alvarez V.A. Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice. J.Neurosci. 2011, 31:126-132.
34. Kubis N., Faucheux B.A., Ransmayr G., Damier P., Duyckaerts C., Henin D., Forette B., Le Charpentier Y., Hauw J.J., Agid Y., Hirsch E.C. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000, 123:366-373.
35. Li H., Han W., Villar V.A., Keever L.B., Lu Q., Hopfer U., Quinn M.T., Felder R.A., Jose P.A., Yu P. D1-like receptors regulate NADPH oxidase activity and subunit expression in lipid raft microdomains of renal proximal tubule cells. Hypertension 2009, 53:1054-1061.
36. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibition reduces oxidative stress and protect dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J.Neurosci. Res. 2005, 81:865-873.
37. Lou M., Blume A., Zhao Y., Gohlke P., Deuschl G., Herdegen T., Culman J. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J.Cereb. Blood Flow Metab. 2004, 24:536-547.
38. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 2008, 29:367-374.
39. McCarthy C.A., Widdop R.E., Denton K.M., Jones E.S. Update on the angiotensin AT(2) receptor. Curr. Hypertens. Rep. 2013, 15:25-30.
40. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 1988, 24:574-576.
41. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Miyoshi K., Ogawa N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res. 2004, 1029:120-123.
42. Muñoz A., Rey P., Guerra M.J., Mendez-Alvarez E., Soto-Otero R., Labandeira-Garcia J.L. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006, 51:112-120.
43. Newman R.P., LeWitt P.A., Jaffe M., Calne D.B., Larsen T.A. Motor function in the normal aging population: treatment with levodopa. Neurology 1985, 35:571-573.
44. Okamura A., Rakugi H., Ohishi M., Yanagitani Y., Takiuchi S., Moriguchi K., Fennessy P.A., Higaki J., Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J.Hypertens. 1999, 17:537-545.
45. Padia S.H., Carey R.M. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch. 2013, 465:99-110.
46. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, New York.
47. Rey P., Lopez-Real A., Sanchez-Iglesias S., Muñoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 2007, 28:555-567.
48. Rodriguez-Pallares J., Parga J.A., Joglar B., Guerra M.J., Labandeira-Garcia J.L. Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. Age (Dordr) 2012, 34:863-880.
49. Rodriguez-Pallares J., Parga J.A., Muñoz A., Rey P., Guerra M.J., Labandeira-Garcia J.L. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J.Neurochem. 2007, 103:145-156.
50. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
51. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. Brain 2012, 135:124-138.
52. Ruiz-Ortega M., Lorenzo O., Ruperez M., Suzuki Y., Egido J. Proinflammatory actions of angiotensin II. Curr. Opin. Nephrol. Hypertens. 2001, 10:321-329.
53. Sanchez-Iglesias S., Rey P., Mendez-Alvarez E., Labandeira-Garcia J.L., Soto-Otero R. Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. Neurochem. Res. 2007, 32:99-105.
54. Shao W., Zhang S.Z., Tang M., Zhang X.H., Zhou Z., Yin Y.Q., Zhou Q.B., Huang Y.Y., Liu Y.J., Wawrousek E., Chen T., Li S.B., Xu M., Zhou J.N., Hu G., Zhou J.W. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin. Nature 2013, 494:90-94.
55. Sheh Y.L., Hsu C., Chan S.H., Chan J.Y. NADPH oxidase- and mitochondrion-derived superoxide at rostral ventrolateral medulla in endotoxin-induced cardiovascular depression. Free Radic. Biol. Med. 2007, 42:1610-1623.
56. Sohn H.Y., Raff U., Hoffmann A., Gloe T., Heermeier T.K., Galle J., Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br. J. Pharmacol. 2000, 131:667-672.
57. Stegbauer J., Lee D.H., Seubert S., Ellrichmann G., Manzel A., Kvakan H., Muller D.N., Gaupp S., Rump L.C., Gold R., Linker R.A. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U.S.A 2009, 106:14942-14947.
58. Suzuki M., Hatano K., Sakiyama Y., Kawasumi Y., Kato T., Ito K. Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and invitro receptor autoradiography. Synapse 2001, 41:285-293.
59. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Egido J. Inflammation and angiotensin II. Int. J. Biochem. Cell. Biol. 2003, 35:881-900.
60. Todd R.D., Carl J., Harmon S., O'Malley K.L., Perlmutter J.S. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J.Neurosci. 1996, 16:7776-7782.
61. Ungvari Z., Csiszar A., Kaley G. Vascular inflammation in aging. Herz 2004, 29:733-740.
62. Valenzuela R., Barroso-Chinea P., Villar-Cheda B., Joglar B., Muñoz A., Lanciego J.L., Labandeira-Garcia J.L. Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. J.Neuropathol. Exp. Neurol. 2010, 69:1130-1142.
63. Villar-Cheda B., Valenzuela R., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol. Aging 2012, 33:204.e1-204.e11.
64. Wang Y., Chan G.L., Holden J.E., Dobko T., Mak E., Schulzer M., Huser J.M., Snow B.J., Ruth T.J., Calne D.B., Stoessl A.J. Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 1998, 30:56-61.
65. Wu D., Teisman P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A 2003, 100:6145-6150.
66. Yanagitani Y., Rakugi H., Okamura A., Moriguchi K., Takiuchi S., Ohishi M., Suzuki K., Higaki J., Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999, 33:335-339.
67. Yang S., Yao B., Zhou Y., Yin H., Zhang M.Z., Harris R.C. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am. J. Physiol. Ren. Physiol. 2012, 302:F742-F749.
68. Yang Z., Asico L.D., Yu P., Wang Z., Jones J.E., Escano C.S., Wang X., Quinn M.T., Sibley D.R., Romero G.G., Felder R.A., Jose P.A. D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290:R96-R104.
69. Yurek D.M., Hipkens S.B., Hebert M.A., Gash D.M., Gerhardt G.A. Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats. Brain Res. 1998, 791:246-256.
70. Zawada W.M., Banninger G.P., Thornton J., Marriott B., Cantu D., Rachubinski A.L., Das M., Griffin W.S., Jones S.M. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J.Neuroinflammation 2011, 8:129.
71. Zeng C., Liu Y., Wang Z., He D., Huang L., Yu P., Zheng S., Jones J.E., Asico L.D., Hopfer U., Eisner G.M., Felder R.A., Jose P.A. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ. Res. 2006, 99:494-500.
72. Zeng C., Luo Y., Asico L.D., Hopfer U., Eisner G.M., Felder R.A., Jose P.A. Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats. Hypertension 2003, 42:787-792.
73. Zhang G.X., Lu X.M., Kimura S., Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc. Res. 2007, 76:204-212.
74. Zhang M.Z., Yao B., Yang S., Wang S., Fan X., Yin H., Fogo A.B., Moeckel G.W., Harris R.C. Intrarenal dopamine inhibits progression of diabetic nephropathy. Diabetes 2012, 61:2575-2584.